

Exploration of the Active Site of Neuronal Nitric Oxide Synthase by the Design and Synthesis of Pyrrolidinomethyl 2-Aminopyridine Derivatives

Haitao Ji,[†] Silvia L. Delker,[‡] Huiying Li,[‡] Pavel Martásek,^{§,¥} Linda J. Roman,[§] Thomas L. Poulos,^{‡} Richard B. Silverman^{*†}*

[†] Department of Chemistry, Department of Molecular Biosciences, and Center for Drug Discovery and Chemical Biology, Northwestern University, Evanston, Illinois 60208-3113.

[‡] Departments of Molecular Biology and Biochemistry, Pharmaceutical Chemistry, and Chemistry, University of California, Irvine, California 92697-3900.

[§] Department of Biochemistry, The University of Texas Health Science Center, San Antonio, Texas 78384-7760.

[¥] Department of Pediatrics and Center for Applied Genomics, 1st School of Medicine, Charles University, Prague, Czech Republic

* Corresponding author: Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208, Phone: (847)491-5653, Fax: (847)491-7713, E-mail: Agman@chem.northwestern.edu.

Table S1. Crystallographic data collection and refinement statistics (1)

| Data set ¹ | nNOS ³ - (3S,4S)-4 | nNOS- (3R,4R)-4 | nNOS ³ - (3R,4S)-4 | nNOS ³ - (3S,4R)-4 |
|--|---|---|---|---|
| PDB code | 3NLK | 3NLM | 3NLN | 3NLO |
| Data collection | | | | |
| Space group | P2 ₁ 2 ₁ 2 ₁ | P2 ₁ 2 ₁ 2 ₁ | P2 ₁ 2 ₁ 2 ₁ | P2 ₁ 2 ₁ 2 ₁ |
| Cell dimensions <i>a, b, c</i> (Å) | 52.1,112.1,164.7 | 52.1,111.1,164.2 | 52.0,112.2,164.8 | 51.4,112.0,164.3 |
| Resolution (Å) | 2.02 (2.05-2.02) | 1.85 (1.88-1.85) | 2.00 (2.03-2.00) | 2.30(2.34 -2.30) |
| <i>R</i> _{sym} or <i>R</i> _{merge} | 0.043 (0.63) | 0.052 (0.56) | 0.051 (0.64) | 0.070 (0.59) |
| <i>I</i> / σ <i>I</i> | 29.1 (2.3) | 31.1 (1.8) | 27.3 (2.2) | 20.3 (1.6) |
| No. unique reflections | 62,972 | 80,355 | 65,190 | 42,244 |
| Completeness (%) | 99.1 (98.0) | 95.8 (89.1) | 98.8 (99.0) | 97.0 (98.2) |
| Redundancy | 4.0 (3.7) | 3.9 (3.9) | 3.9 (3.9) | 3.2 (3.4) |
| Refinement | | | | |
| Resolution (Å) | 2.02 | 1.85 | 2.00 | 2.29 |
| No. reflections | 59,732 | 76,329 | 61,889 | 40,091 |
| <i>R</i> _{work} / <i>R</i> _{free} ² | 0.174/0.211 | 0.189/0.222 | 0.189/0.225 | 0.196/0.262 |
| No. atoms | | | | |
| Protein | 6653 | 6703 | 6653 | 6653 |
| Ligand/ion | 183 | 188 | 183 | 183 |
| Water | 375 | 381 | 306 | 105 |
| Mean <i>B</i> -factor | 51.83 | 44.88 | 53.34 | 69.04 |
| R.m.s. deviations | | | | |
| Bond lengths (Å) | 0.014 | 0.014 | 0.014 | 0.019 |
| Bond angles (°) | 1.388 | 1.400 | 1.399 | 1.718 |

| Data set ¹ | eNOS- (3S,4S)-4 | eNOS- (3R,4R)-4 | eNOS- (3R,4S)-4 | eNOS- (3S,4R)-4 |
|--|---|---|---|---|
| PDB code | 3NLD | 3NLE | 3NLF | 3NLG |
| Data collection | | | | |
| Space group | P2 ₁ 2 ₁ 2 ₁ | P2 ₁ 2 ₁ 2 ₁ | P2 ₁ 2 ₁ 2 ₁ | P2 ₁ 2 ₁ 2 ₁ |
| Cell dimensions <i>a, b, c</i> (Å) | 57.4,106.9,157.4 | 58.5,107.6, 158.3 | 58.1,107.1,157.3 | 57.9,106.9,157.0 |
| Resolution (Å) | 2.28 (2.32-2.28) | 1.95 (1.98-1.95) | 2.32 (2.36-2.32) | 2.38 (2.42-2.38) |
| <i>R</i> _{sym} or <i>R</i> _{merge} | 0.118 (0.571) | 0.056 (0.552) | 0.052 (0.331) | 0.091 (0.611) |
| <i>I</i> / σ | 14.7 (2.0) | 20.9 (2.0) | 23.6 (4.5) | 13.4 (1.9) |
| No. unique reflections | 44,220 | 72,238 | 43,117 | 39,666 |
| Completeness (%) | 98.9 (96.0) | 98.3 (99.5) | 99.4 (100.0) | 98.7 (99.6) |
| Redundancy | 4.7 (3.0) | 3.6 (3.6) | 3.8 (3.8) | 3.7 (3.7) |
| Refinement | | | | |
| Resolution (Å) | 2.28 | 1.95 | 2.32 | 2.38 |
| No. reflections | 41,942 | 69,838 | 40,909 | 37,644 |
| <i>R</i> _{work} / <i>R</i> _{free} ² | 0.222/0.292 | 0.184/0.206 | 0.174/0.224 | 0.171/0.231 |
| No. atoms | | | | |
| Protein | 6511 | 6418 | 6418 | 6425 |
| Ligand/ion | 201 | 201 | 201 | 201 |
| Water | 138 | 292 | 333 | 361 |
| Mean <i>B</i> -factor | 60.21 | 53.11 | 37.67 | 33.33 |
| R.m.s. deviations | | | | |
| Bond lengths (Å) | 0.021 | 0.012 | 0.012 | 0.012 |
| Bond angles (°) | 1.930 | 1.280 | 1.349 | 1.429 |

¹ See Fig. 3 for chemical formula of inhibitors.

² *R*_{free} was calculated with the 5% of reflections set aside throughout the refinement. The set of reflections for the *R*_{free} calculation was kept the same for all data sets of each NOS isoform according to that used in the starting model.

³ The nNOS R349A mutant used.

Table S2. Crystallographic data collection and refinement statistics (2)

| Data set ¹ | DMnNOS- (3S,4S)-4 | DMnNOS- (3R,4R)-4 | DMnNOS- (3R,4S)-4 | TMnNOS- (3R,4R)-4 |
|--|---|---|---|---|
| PDB code | 3NLP | 3NLQ | 3NLR | 3NLJ |
| Data collection | | | | |
| Space group | P2 ₁ 2 ₁ 2 ₁ | P2 ₁ 2 ₁ 2 ₁ | P2 ₁ 2 ₁ 2 ₁ | P2 ₁ 2 ₁ 2 ₁ |
| Cell dimensions <i>a</i> , <i>b</i> , <i>c</i> (Å) | 51.8, 111.0, 164.6 | 51.6, 111.2, 164.0 | 51.5, 110.6, 164.1 | 51.8, 111.1, 163.9 |
| Resolution (Å) | 2.03 (2.07-2.03) | 2.15 (2.19-2.15) | 2.10 (2.14-2.10) | 2.20 (2.24-2.20) |
| <i>R</i> _{sym} or <i>R</i> _{merge} | 0.049 (0.689) | 0.048 (0.595) | 0.060 (0.383) | 0.066(0.625) |
| <i>I</i> / σ <i>I</i> | 28.0(2.3) | 24.8 (2.3) | 21.4 (1.6) | 21.4(1.9) |
| No. unique reflections | 62,123 | 52,037 | 52,286 | 48,289 |
| Completeness (%) | 98.8 (97.1) | 99.3 (99.4) | 93.6 (68.7) | 98.7 (92.0) |
| Redundancy | 3.9 (3.5) | 3.6 (3.6) | 3.7 (2.7) | 3.9 (3.5) |
| Refinement | | | | |
| Resolution (Å) | 2.03 | 2.15 | 2.10 | 2.20 |
| No. reflections | 59,003 | 49,387 | 49,547 | 45,803 |
| <i>R</i> _{work} / <i>R</i> _{free} ² | 0.187/0.228 | 0.204/0.259 | 0.186/0.235 | 0.201/0.268 |
| No. atoms | | | | |
| Protein | 6669 | 6663 | 6657 | 6642 |
| Ligand/ion | 183 | 187 | 183 | 183 |
| Water | 284 | 215 | 201 | 226 |
| Mean <i>B</i> -factor | 56.97 | 61.82 | 63.07 | 49.50 |
| R.m.s. deviations | | | | |
| Bond lengths (Å) | 0.017 | 0.018 | 0.018 | 0.014 |
| Bond angles (°) | 1.493 | 1.742 | 1.794 | 1.546 |

| Data set ¹ | SMeNOS- (3S,4S)-4 | SMeNOS- (3R,3R)-4 |
|--|---|---|
| PDB code | 3NLH | 3NLL |
| Data collection | | |
| Space group | P2 ₁ 2 ₁ 2 ₁ | P2 ₁ 2 ₁ 2 ₁ |
| Cell dimensions | | |
| <i>a</i> , <i>b</i> , <i>c</i> (Å) | 57.8, 106.8, 156.9 | 58.0, 106.8, 156.6 |
| Resolution (Å) | 2.10 (2.14-2.10) | 1.98 (2.01-1.98) |
| <i>R</i> _{sym} or <i>R</i> _{merge} | 0.092 (0.771) | 0.077 (0.730) |
| <i>I</i> / σ | 13.86 (1.74) | 18.08 (1.86) |
| No. unique reflections | 57,492 | 68,424 |
| Completeness (%) | 99.4 (100.0) | 99.5 (98.3) |
| Redundancy | 4.0 (4.0) | 4.0 (3.9) |
| Refinement | | |
| Resolution (Å) | 2.10 | 1.98 |
| No. reflections | 54,574 | 64,937 |
| <i>R</i> _{work} / <i>R</i> _{free} ² | 0.173/0.212 | 0.169/0.203 |
| No. atoms | | |
| Protein | 6410 | 6429 |
| Ligand/ion | 201 | 201 |
| Water | 516 | 626 |
| Mean <i>B</i> -factor | 29.82 | 30.67 |
| R.m.s. deviations | | |
| Bond lengths (Å) | 0.010 | 0.009 |
| Bond angles (°) | 1.310 | 1.313 |

¹ See Fig. 3 for chemical formula of inhibitors. DMnNOS: nNOS D597N/M336V mutant; TMnNOS: nNOS D597N/M336V/Y706A mutant; SMeNOS: eNOS N368D mutant.

² *R*_{free} was calculated with the 5% of reflections set aside throughout the refinement. The set of reflections for the *R*_{free} calculation was kept the same for all data sets of each NOS isoform according to that used in the starting model.





Figure S1. Crystallographic binding conformations of four enantiomerically pure isomers of **4** [A: (3'S, 4'S)-**4**, B: (3'R, 4'R)-**4**, C: (3'R, 4'S)-**4**, D: (3'S, 4'R)-**4**] with bovine eNOS. Shown also the $2F_o - F_c$ electron density for the ligands contoured at 1σ . The active site residues and ligands are represented in an atom-type style (carbons in green or cyan (chain B), nitrogens in blue, oxygen in red, and sulfur in yellow). The important H-bonds between the residues, structural water, cofactors, and inhibitors are depicted with dashed lines.

AutoDock Analysis. AutoDock 3.0.5 was employed to perform the docking calculations.¹ For the protein structure (PDB id: 1P6I), polar hydrogen atoms were added, and Kollman united atom charges were assigned.² Hydrogens were also added to the heme and H₄B, and charges were calculated by the Gasteiger–Marsili method.³ The nonpolar hydrogen atoms of heme and H₄B were removed manually, and their charges were united with the bonded carbon atoms. Atomic solvation parameters and fragmental volumes were assigned using the AddSol utility. The 3D structures of the

ligands were built and partial atomic charges were also calculated using the Gasteiger–Marsili method. The rotatable bonds in the ligands were defined using another AutoDock 3.0 auxiliary program, AutoTors, which also unites the nonpolar hydrogens and partial atomic charges to the bonded carbon atoms. The grid maps were calculated using AutoGrid. The dimensions of the grid box was $27 \times 26 \times 31 \text{ \AA}$, and the grid spacing was set to 0.375 \AA . Docking was performed using the Lamarckian genetic algorithm (LGA), and the pseudo-Solis and Wets method were applied for the local search. The procedure in detail used was that previously described.⁴⁻⁶

Scheme 1.



(±)-tert-Butyl

{6-[[cis-1'-(2"-tert-butoxycarbonylaminoethyl)-4'-(3"-hydroxypropylamino)-pyrrolidin-3'-yl]methyl]pyridin-2-yl}-carbamate (41b) and (±)-tert-Butyl {6-[[trans-1'-(2"-tert-butoxycarbonylaminoethyl)-4'-(3"-hydroxypropylamino)-pyrrolidin-3'-yl]methyl]pyridin-2-yl}-carbamate (42b)

The procedure to prepare **41b** and **42b** is the same as that to prepare **41a** and **42a** except using 3-amino-1-propanol (0.113 g, 0.0015 mol) instead of 3-phenyl-1-propylamine. The yield was 55% (0.271 g). The *cis* isomer (**41b**) and the *trans* isomer (**42b**) can be separated by silica gel column chromatography (CH₂Cl₂ : EtOAc : MeOH : Et₃N = 7.6 : 2 : 0.4 : 0.5). The ratio of the *cis* isomer to the *trans* isomer was 45 : 55.

41b: (*R*_f = 0.25, pale-yellow oil, 0.122 g): ¹H NMR (CDCl₃, 500 MHz): δ 7.737 (d, 1H, J=8Hz), 7.556 (t, 2H, J=8Hz), 6.7955 (d, 1H, J=7.5Hz), 5.163 (brs, 1H), 3.865-3.798 (m, 2H), 3.660-3.616 (q, 2H), 3.175 (m, 2H), 2.891-2.870 (m, 2H), 2.819-2.790 (m, 1H), 2.759-2.715 (m, 1H), 2.660-2.645 (m, 3H) 2.584-2.558 (m, 4H), 2.456 (m, 1H), 1.751-1.731 (m, 2H), 1.523 (s, 9H), 1.453 (s, 9H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 159.306 (1C), 156.300 (1C), 152.656 (1C), 151.572 (1C), 138.802 (1C), 117.951 (1C), 109.726 (1C), 81.006 (1C), 79.276 (1C), 64.707 (1C), 59.377 (1C), 59.110 (1C), 57.694 (1C), 55.276 (1C), 48.370 (1C), 41.883 (1C), 39.159 (1C), 36.625 (1C), 31.264 (1C), 28.648 (3C), 28.486 (3C). MS (ESI, CH₃OH): [C₂₅H₄₃N₅O₅] *m/z* 494.4 ([M+H]⁺).

42b: (*R*_f = 0.2, pale-yellow oil, 0.149 g): ¹H NMR (CDCl₃, 500 MHz): δ 8.338 (brs, 1H), 7.784 (d, 1H, J=8Hz), 7.566 (t, 1H, J=8Hz), 6.7995 (d, 1H, J=7.5Hz), 5.247 (brs, 1H), 3.906-3.815 (m, 2H), 3.628-3.585 (q, 1H) 3.224 (m, 2H), 3.064 (m, 1H), 2.987-2.797 (m, 6H), 2.691-2.514 (m, 4H), 2.217-2.186 (m, 1H), 1.887-1.881 (m, 1H), 1.786 (m, 1H), 1.524 (s, 9H), 1.453 (s, 9H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 158.203 (1C), 156.319 (1C), 152.961 (1C), 152.056 (1C), 138.748 (1C), 118.198 (1C), 110.233 (1C), 80.886 (1C), 79.250 (1C), 63.535 (1C), 63.110 (1C), 58.990 (1C), 57.968 (1C), 54.808 (1C), 47.794 (1C), 42.885 (1C), 41.453 (1C), 38.900 (1C), 29.937 (1C), 28.652 (3C), 28.482 (3C). MS (ESI, CH₃OH): [C₂₅H₄₃N₅O₅] *m/z* 494.4 ([M+H]⁺).

(±)-6-{{cis-1'-(2"-aminoethyl)-4'-[(3"-phenylpropyl)amino]pyrrolidin-3'-yl}methyl}pyridin-2-amine tetrahydrochloride (8). The procedure to prepare **8** is the same as that to prepare **9** except using **41a** (0.111 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.100 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.842 (t, 1H, J=8.5Hz), 7.406-7.283 (m, 5H), 6.928 (d, 1H, J=9Hz), 6.808 (d, 1H, J=7Hz), 4.354-4.311 (m, 1H), 4.102-4.061 (m, 1H), 3.743-3.580 (m, 5H), 3.447-3.357 (m, 3H), 3.291-3.111 (m, 3H), 2.936-2.883 (m, 1H), 2.786-2.748 (m, 2H), 2.125-2.097 (m, 2H). ¹³C NMR (D₂O, 125.7 MHz): δ 154.876 (1C), 144.744 (1C), 144.164 (1C), 140.516 (1C), 128.995 (2C), 128.663 (2C), 126.748 (1C), 112.666 (1C), 112.558 (1C), 56.788 (1C), 56.405 (1C), 54.359 (1C), 52.042 (1C), 47.442 (1C), 37.848 (1C), 35.148 (1C), 31.856 (1C), 29.395 (1C), 27.120 (1C). MS (ESI, CH₃CN-H₂O): [C₂₁H₃₁N₅] *m/z* 354.3 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 354.2652, Found: 354.2651.


(±)-3-{{cis-1'-(2"-aminoethyl)-4'-[(6"-aminopyridin-2"-yl)methyl]pyrrolidin-3'-yl}amino}propan-1-ol tetrahydrochloride (10). The procedure to prepare **10** is the same as that to prepare **8** except using **41b** (0.097 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.087 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.847 (t, 1H, J=8Hz), 6.931 (d, 1H, J=9Hz), 6.835 (d, 1H, J=7Hz), 4.421 (m, 1H),

4.202 (m, 1H), 3.801-3.665 (m, 6H), 3.453-3.410 (m, 4H), 3.353-3.284(m, 3H), 2.976-2.922 (m, 1H), 2.031-1.982 (m, 2H). ¹³C NMR (D₂O, 125.7 MHz): δ 154.899 (1C), 144.756 (1C), 144.032 (1C), 112.701 (1C), 112.608 (1C), 56.804 (1C), 56.436 (1C), 54.344 (1C), 52.366 (1C), 52.084 (1C), 46.092 (1C), 37.921 (1C), 35.008 (1C), 29.360 (1C), 27.817 (1C). MS (ESI, CH₃OH-H₂O): [C₁₅H₂₇N₅O] *m/z* 294.4 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 294.2288, Found: 294.2288.


(±)-3-{{trans-1'-(2''-aminoethyl)-4'-[(6''-aminopyridin-2''-yl)methyl]pyrrolidin-3'-yl}amino}propan-1-ol tetrahydrochloride (11). The procedure to prepare **11** is the same as that to prepare **8** except using **42b** (0.097 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.087 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.846 (t, 1H, J=8.5Hz), 6.9215 (d, 1H, J=8.5Hz), 6.813 (d, 1H, J=7Hz), 4.154-2.954 (m, 16H), 2.062-1.932 (m, 2H). ¹³C NMR (D₂O, 125.7 MHz): δ 154.799 (1C), 144.771 (2C), 112.770 (1C), 112.550 (1C), 59.678 (1C), 57.346 (1C), 55.187 (1C), 52.324 (1C), 51.461 (1C), 45.082 (1C), 39.952 (1C), 35.306 (1C), 34.212 (1C), 28.010 (1C). MS (ESI, CH₃OH-H₂O): [C₁₅H₂₇N₅O] *m/z* 294.4 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 294.2288, Found: 294.2283.

Scheme 2.

A.



B.



(±)-trans-tert-Butyl

3-[[6'-(tert-butoxycarbonylamino)pyridin-2'-yl]methyl]-4-[2'-(dimethylamino)ethyl]pyrrolidine-1-carboxylate (46a). The procedure to prepare 46a is the same as that to prepare 42a except using 45 (0.196 g, 0.5 mmol) which was prepared in the previous study^{5,6} and N^l, N^l -dimethylethane-1,2-diamine (0.049 g, 0.55 mmol) instead of 40 (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : $\text{Et}_3\text{N} = 4 : 6 : 0.5$, the isomer with lower R_f value, $R_f = 0.1$) to afford a pale-yellow oil (0.

0.97 g, 60%, diastereomer ratio: *cis* : *trans* = 30 : 70). ¹H NMR (CDCl₃, 500 MHz): δ (7.891+7.826) (brs, 1H), 7.764-7.736 (m, 1H), 7.567-7.538 (m, 1H), 6.775 (d, 1H, J=6Hz), 3.782-3.748 (m, 0.5H), 3.693-3.610 (m, 1H), 3.574-3.537 (m, 0.5 H), 3.147-3.035 (m, 2H), 2.990-2.980 (m, 1H), 2.873-2.837 (m, 1H), 2.770-2.605 (m, 3H), 2.529-2.311 (m, 3H), 2.220 (m, 6H), 1.521 (s, 9H), 1.449 (s, 9H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 158.233 (1C), 154.674 (1C), 152.767 (1C), (151.807+151.742) (1C), 138.646 (1C), 117.983 (1C), (110.315+110.219) (1C), 80.967 (1C), 79.237 (1C), (63.624+62.993) (1C), (59.403+59.360) (1C), (52.509+52.037) (1C), (50.536+50.172) (1C), 46.091 (1C), 45.541 (2C), (43.684+42.984) (1C), (40.199+40.110) (1C), 28.670 (3C), 28.469 (3C). MS (ESI, CH₃OH): [C₂₄H₄₁N₅O₄] *m/z* 464.6 ([M+H]⁺).

(±)-*trans-tert*-Butyl

3-{2'-[benzyl(*tert*-butoxycarbonyl)amino]ethylamino}-4-[[6'-(*tert*-butoxycarbonyl amino)pyridin-2'-yl]methyl]pyrrolidine-1-carboxylate (46b). The procedure to prepare **46b** is the same as that to prepare **42a** except using **45** (0.196 g, 0.5 mmol)^{1,2} and *N*^l-benzyl *N*^l-Boc-ethane-1,2-diamine (0.138 g, 0.55 mmol) which was prepared in the previous study² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9 : 1 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.107 g, 62%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.756-7.745 (m, 1H), 7.555-7.514 (m, 1H), 7.407-7.234 (m, 6H), 6.788-6.773 (m, 1H), 4.570-4.448 (m, 2H), 3.764-3.674 (m, 0.5H), 3.660-3.643 (m, 0.5H), 3.622-3.586 (m, 0.5H), 3.546-3.511 (m, 0.5H), 3.297-2.935 (m, 7H), 2.888-2.831 (m, 1H), 2.673 (m, 1H), 2.424-2.356 (m, 0.5H), 2.314-2.300 (m, 0.5H), 1.506-1.454 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 158.067 (1C), 154.554 (1C), (152.604+152.569) (1C), (151.784+151.703) (1C), (138.765+138.680) (1C), 138.630 (1C), 128.460 (2C), 127.945 (1C), 127.048 (2C), (117.786+117.755) (1C), (109.855+109.793) (1C), 80.646 (1C), 80.106 (1C), 79.211 (1C), (62.943+62.374) (1C), (52.408+51.963) (1C), (50.680+50.192) (1C), (50.304+49.971) (1C), (48.291+48.177) (1C), (46.287+46.250) (1C), (43.824+43.205) (1C), (39.843+39.738) (1C), 28.662 (3C), 28.577 (3C), 28.337 (3C). MS (ESI, CH₃OH): [C₃₄H₅₁N₅O₆] *m/z* 626.3 ([M+H]⁺).

(±)-*trans-tert*-Butyl

3-[(*R*)-2'-(*tert*-butoxycarbonylamino)-3'-phenylpropylamino]-4-[[6'-(*tert*-butoxycarbonylamino)pyridin-2'-yl]methyl]pyrrolidine-1-carboxylate (46c). The procedure to prepare **46c** is the same as that to prepare **42a** except using **45** (0.196 g, 0.5 mmol)^{1,2} and (*R*)-*tert*-butyl 1-amino-3-phenylpropan-2-ylcarbamate (0.138 g, 0.55 mmol)² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9 : 1 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.095 g, 55%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.756 (m, 1H), 7.555-7.538 (m, 1H), 7.406-7.161 (m, 6H), 6.7575 (d, 1H, J=7.5 Hz), 4.829-4.776 (m, 1H), 3.878-3.839 (m, 1H), 3.660-3.642 (m, 0.5H), 3.660-3.554 (m, 1H), 3.476-3.442 (m, 0.5H), 3.135-2.531 (m, 9H), 2.406-2.397 (m, 0.5H), 2.322-2.269 (m, 0.5H), 1.514 (s, 9H), 1.443 (s, 9H), 1.410 (m, 9H). ¹³C NMR(CDCl₃, 125.7 MHz): δ (158.318+158.109) (1C), (155.777+155.715) (1C) 154.686 (1C), 152.461 (1C), 151.610 (1C), 138.634 (1C), (138.592+138.178) (1C), (129.423+129.392) (2C), (128.781+128.572) (2C), 126.525 (1C), 118.002 (1C),

109.836 (1C), 80.909 (1C), 79.358 (2C), (62.308+62.154+61.504+61.326) (1C), (51.952-51.422) (2C), 50.133-49.627 (1C), (44.110+44.002+43.576+43.464) (1C), (40.071-38.876) (2C), 28.631 (3C), 28.507 (3C), 28.395 (3C). MS (APCI, CH₂Cl₂): [C₃₄H₅₁N₅O₆] *m/z* 626.2 ([M+H]⁺).

(±)-*trans-tert-Butyl*

3-[(*S*)-2'-(*tert*-butoxycarbonylamino)-3'-phenylpropylamino]-4-[[6'-(*tert*-butoxycarbonylamino)pyridin-2'-yl]methyl]pyrrolidine-1-carboxylate (46d). The procedure to prepare **46d** is the same as that to prepare **42a** except using **45** (0.196 g, 0.5 mmol)^{1,2} and (*S*)-*tert*-butyl 1-amino-3-phenylpropan-2-ylcarbamate (0.138 g, 0.55 mmol)² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9 : 1 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.103 g, 60%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.764 (m, 1H), 7.549-7.544 (m, 2H), 7.276-7.161 (m, 5H), 6.751 (d, 1H, *J* = 7 Hz), 4.923 (m, 1H), 3.888-3.838 (m, 1H), 3.661 (m, 0.5H), 3.598-3.553 (m, 1H), 3.473-3.460 (m, 0.5H), 3.133-2.537 (m, 9H), 2.399 (m, 0.5H), 2.311 (m, 0.5H), 1.511 (s, 9H), 1.443 (s, 9H), 1.405 (m, 9H). ¹³C NMR (CDCl₃, 125.7 MHz): δ (158.218+158.036) (1C), (155.703+155.645) (1C) 154.566 (1C, 19), (152.461+152.403) (1C), 151.591 (1C), 138.530 (1C), (138.483+138.139) (1C), (129.334+129.303) (2C), 128.460 (2C), 126.413 (1C), 117.879 (1C), 109.770 (1C), 80.762 (1C), 79.222 (2C), (62.208+62.007+61.399+60.382) (1C), (51.820-51.313) (2C), 50.056-49.538 (1C), (43.986+43.874+43.475+43.359) (1C), (39.564-38.787) (2C), 28.546 (3C), 28.418 (3C), 28.306 (3C). MS (ESI, CH₃OH): [C₃₄H₅₁N₅O₆] *m/z* 626.6 ([M+H]⁺).

(±)-*trans-tert-Butyl*

3-[[6'-(*tert*-butoxycarbonylamino)pyridin-2'-yl]methyl]-4-[(*S*)-1'-(*tert*-butoxycarbonyl)pyrrolidin-3'-yl]amino]pyrrolidine-1-carboxylate (46e). The procedure to prepare **46e** is the same as that to prepare **42a** except using **45** (0.196 g, 0.5 mmol)^{1,2} and (*S*)-(-)-1-Boc-3-aminopyrrolidine (0.103 g, 0.55 mmol) instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 8 : 2 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.093 g, 60%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.753-7.737 (m, 1H), 7.564-7.552 (m, 1H), 7.431-7.291 (m, 1H), 6.780 (m, 1H), 3.774 (m, 0.5H), 3.711-3.698 (m, 0.5H), 3.581 (m, 1H), 3.474-3.298 (m, 5H), 3.117-2.897 (m, 5H), 2.619-2.598 (m, 1H), 2.414 (m, 0.5H), 2.325 (m, 0.5H), 1.986 (m, 1H), 1.521 (s, 9H), 1.461-1.450 (m, 18H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 158.144 (1C), (154.717+154.647+154.566) (2C), 152.392 (1C), 151.567 (1C), 138.661 (1C), (118.103+117.960) (1C), 109.828 (1C), 80.990 (1C), 79.439 (1C), 79.308 (1C), (61.055+60.927+60.711+60.111+59.681) (1C), (56.544+56.378+55.743+55.476+55.120) (1C), (52.726+52.555+52.029+51.453) (2C), (49.928+49.677) (1C), (44.404+44.121+44.005+43.769) (2C), (40.063+39.773+39.676) (1C), (33.138+32.376+32.032+31.444) (1C), 28.620 (6C), 28.376 (3C). MS (ESI, CH₃OH): [C₂₉H₄₇N₅O₆] *m/z* 562.7 ([M+H]⁺); *m/z* 584.6 ([M+Na]⁺); *m/z* 1123.6 ([2M+H]⁺); *m/z* 1145.3 ([2M+Na]⁺).

(±)-*trans-tert-Butyl*

3-{{6'-[(*tert*-butoxycarbonyl)amino]pyridin-2'-yl)methyl}-4-[[*(R)*-1'-(*tert*-butoxycarbonyl)pyrrolidin-3'-yl]amino]pyrrolidine-1-carboxylate (46f). The procedure to prepare **46f** is the same as that to prepare **42a** except using **45** (0.196 g, 0.5 mmol)^{1,2} and (*R*)-(+)-1-Boc-3-aminopyrrolidine (0.103 g, 0.55 mmol) instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 8 : 2 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.100 g, 65%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.752-7.736 (m, 1H), 7.563-7.550 (m, 1H), 7.449-7.314 (m, 1H), 6.789-6.778 (m, 1H), 3.773 (m, 0.5H), 3.709-3.697 (m, 0.5H), 3.592-3.560 (m, 1H), 3.473-3.296 (m, 5H), 3.113-2.898 (m, 5H), 2.618 (m, 1H), 2.411 (m, 0.5H), 2.325 (m, 0.5H), 1.984-1.974 (m, 1H), 1.520 (s, 9H), 1.461-1.449 (m, 18H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 158.137 (1C), (154.682+154.616) (2C), 152.380 (1C), 151.552 (1C), 138.634 (1C), (118.084+117.937) (1C), 109.801 (1C), 80.956 (1C), 79.400 (1C), 79.273 (1C), (61.036+60.896+60.691+60.099+59.654) (1C), (56.532+56.358+55.735+55.453+55.093) (1C), (52.710+52.536+52.006+51.851+51.437) (2C), (49.913+49.658) (1C), (44.385+44.102+43.986+43.746) (2C), (40.032+39.754+39.657) (1C), (33.119+32.357+32.009+31.428) (1C), 28.600 (6C), 28.356 (3C). MS(ESI, CH₃OH): [C₂₉H₄₇N₅O₆] *m/z* 562.7 ([M+H]⁺); *m/z* 584.6 ([M+Na]⁺); *m/z* 1123.6 ([2M+H]⁺); *m/z* 1145.3 ([2M+Na]⁺).

(±)-*trans-tert*-Butyl

3-[[*(S)*-1'-benzylpyrrolidin-3'-yl]amino]-4-{{6'-[(*tert*-butoxycarbonyl)amino]pyridin-2'-yl)methyl}pyrrolidine-1-carboxylate (46g). The procedure to prepare **46g** is the same as that to prepare **42a** except using **45** (0.196 g, 0.5 mmol)^{1,2} and (*S*)-(+)-1-benzyl-3-aminopyrrolidine (0.097 g, 0.55 mmol) instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 7 : 3 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.096 g, 50%, diastereomer ratio: *cis* : *trans* = 30 : 70). ¹H NMR (CDCl₃, 500 MHz): δ (8.807+8.763) (brs, 1H), 7.803-7.736 (m, 1H), 7.568-7.536 (m, 1H), 7.364-7.223 (m, 5H), 6.777-6.747 (m, 1H), 4.006-3.402 (m, 4H), 3.364-3.255 (m, 1H), 3.160-2.899 (m, 4H), 2.838-2.818 (m, 1H), 2.775-2.617 (m, 3H), 2.574-2.196 (m, 4H), (1.523+1.503) (s, 9H), 1.436 (s, 9H). ¹³C NMR (CDCl₃, 125.7 MHz): δ (158.191+158.140) (1C), (154.616+154.484) (1C), (152.894+152.484) (1C), (151.896+151.846+151.525) (1C), 138.905 (1C), (138.669+138.553) (1C), (128.990+128.935) (2C), 128.347 (2C), 127.059 (1C), (118.064+117.886+117.844) (1C), (110.199+110.13+110.056+109.971) (1C), 80.983-80.913 (1C), (79.323+79.292) (1C), (61.929+61.643+61.531+61.279) (1C), 60.614 (1C), (60.498+60.347+59.956) (1C) (58.594+58.471) (1C), (56.022+55.968+55.875) (1C), (53.329+53.143+53.085) (1C), (52.973+52.479+51.956) (1C), (50.865+50.509+50.087+49.805) (1C), (44.094+43.812+43.491+43.154) (1C), (40.651+40.524+39.738) (1C), (33.363+31.927+31.846) (1C), 28.627 (3C), (28.519+28.384) (3C). MS (ESI, CH₃OH): [C₃₁H₄₅N₅O₄] *m/z* 552.5 ([M+H]⁺).

(±)-*trans-tert*-Butyl

3-[[*(R)*-1'-benzylpyrrolidin-3'-yl]amino]-4-{{6'-[(*tert*-butoxycarbonyl)amino]pyridin-2'-yl)methyl}pyrrolidine-1-carboxylate (46h). The procedure to prepare **46h** is

the same as that to prepare **42a** except using **45** (0.196 g, 0.5 mmol)^{1,2} and (*R*)-(-)-1-benzyl-3-aminopyrrolidine (0.097 g, 0.55 mmol) instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 7 : 3 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.096 g, 50%, diastereomer ratio: *cis* : *trans* = 30 : 70). ¹H NMR (CDCl₃, 500 MHz): δ (8.814+8.770) (brs, 1H), 7.803-7.736 (m, 1H), 7.568-7.520 (m, 1H), 7.364-7.222 (m, 5H), 6.776-6.747 (m, 1H), 4.007-3.401 (m, 4H), 3.364-3.225 (m, 1H), 3.159-2.935 (m, 4H), 2.856-2.819 (m, 1H), 2.775-2.616 (m, 3H), 2.576-2.163 (m, 4H), (1.523+1.502) (s, 9H), 1.436 (s, 9H). ¹³C NMR (CDCl₃, 125.7 MHz): δ (158.187+158.117) (1C), (154.616+154.473) (1C), (152.887+152.496) (1C), (151.892+151.842+151.517) (1C), 138.901 (1C), (138.661+138.541) (1C), (128.986+128.932) (2C), 128.340 (2C), 127.051 (1C), (118.057+117.879+117.836) (1C), (110.192+110.130+110.052+109.967) (1C), 80.971-80.905 (1C), (79.311+79.280) (1C), (61.933+61.631+61.519+61.279) (1C), 60.606 (1C), (60.490+60.339+59.960) (1C) (58.575+58.459) (1C), (56.018+55.964+55.871) (1C), (53.321+53.132+53.074) (1C), (52.965+52.455+51.956) (1C), (50.861+50.725+50.083+49.801) (1C), (44.087+43.804+43.483+43.139) (1C), (40.651+40.524+39.734) (1C), (33.351+31.952+31.844) (1C), 28.620 (3C), (28.511+28.376) (3C). MS (ESI, CH₃OH): [C₃₁H₄₅N₅O₄] *m/z* 552.6 ([M+H]⁺).

***N*¹-{(±)-*trans*-4-[(6-aminopyridin-2-yl)methyl]pyrrolidin-3-yl}-*N*²,*N*²-dimethylethane-1,2-diamine tetrahydrochloride (**13**)**. The procedure to prepare **13** is the same as that to prepare **8** except using **46a** (0.093 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.081 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.848 (t, 1H, *J*=8.5Hz), 6.927 (d, 1H, *J*=9Hz), 6.8295 (d, 1H, *J*=7.5Hz), 4.113-4.018 (m, 2H), 3.777-3.679 (m, 2H), 3.654-3.612 (m, 4H), 3.374-3.328 (m, 2H), 3.174-3.133 (m, 1H), 2.997 (s, 6H), 2.962-2.932 (m, 1H). ¹³C NMR (D₂O, 125.7 MHz): δ 154.793 (1C), 144.835 (1C), 144.595 (1C), 112.860 (1C), 112.612 (1C), 60.926 (1C), 52.558 (1C), 48.562 (1C), 46.492 (1C), 43.637 (2C), 41.606 (1C), 40.538 (1C), 33.590 (1C). MS (ESI, CH₃OH): [C₁₄H₂₅N₅] *m/z* 264.2 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 264.2183, Found: 264.2179.

***N*¹-{(±)-*trans*-4-[(6-aminopyridin-2-yl)methyl]pyrrolidin-3-yl}-*N*²-benzylethane-1,2-diamine tetrahydrochloride (**14**)**. The procedure to prepare **14** is the same as that to prepare **8** except using **46b** (0.125 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.094 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.855 (t, 1H, *J*=8Hz), 7.548-7.496 (m, 5H), 6.932 (d, 1H, *J*=9Hz), 6.829 (d, 1H, *J*=7Hz), 4.350 (s, 2H), 4.034-3.997 (m, 2H), 3.725-3.683 (m, 2H), 3.535 (m, 4H), 3.370-3.301 (m, 2H), 3.116-3.111 (m, 1H), 2.976-2.926 (m, 1H). ¹³C NMR (D₂O, 125.7 MHz): δ 154.793 (1C), 144.827 (1C), 144.699 (1C), 130.180 (1C), 130.134 (1C), 130.041 (2C), 129.542 (2C), 112.794 (1C), 112.574 (1C), 60.775 (1C), 51.862 (1C), 48.566 (1C), 46.620 (1C), 42.937 (2C), 40.627 (1C), 33.605 (1C). MS (ESI, CH₃OH): [C₁₉H₂₇N₅] *m/z* 326.2 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 326.2339, Found: 326.2331.

(*R*)-*N*¹-{(±)-*trans*-4'-[(6''-aminopyridin-2''-yl)methyl]pyrrolidin-3'-yl}-3-phenylpropane-1,2-diamine tetrahydrochloride (15**)**. The procedure to prepare **15** is the same as that to prepare **8** except using **46c** (0.125 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.094 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ

7.834 (t, 1H, J=8.5 Hz), 7.436-7.342 (m, 5H), 6.917 (d, 1H, J=9Hz), 6.799 (m, 1H), 3.998-3.933 (m, 3H), 3.715-3.657 (m, 2H), 3.531-3.011 (m, 7H), 2.958-2.886 (m, 1H). ¹³C NMR (D₂O, 125.7 MHz): δ 154.704 (1C), 144.839 (1C), (144.750+144.726) (1C), (134.006+133.971) (1C), 129.561 (4C), 128.281 (1C), 112.806 (1C), 112.535 (1C), (61.197+61.046) (1C), (50.554+50.388) (1C), (48.728+48.690) (1C), (48.264+48.156) (1C), (46.929+46.898) (1C), (40.619+40.453) (1C), (36.549+36.522) (1C), (33.857+33.749) (1C). MS (ESI, CH₃OH): [C₁₉H₂₇N₅] *m/z* 326.2 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 326.2339, Found: 326.2334. Comb. Anal. (C₁₉H₃₁Cl₄N₅ · 1.065 H₂O), Calcd: C, 46.53; H, 6.81; N, 14.28; Found: C, 46.93; H, 7.01; N, 13.72.

(S)-N¹-{(±)-trans-4'-[(6''-aminopyridin-2''-yl)methyl]pyrrolidin-3'-yl}-3-phenylpropane-1,2-diamine tetrahydrochloride (16). The procedure to prepare **16** is the same as that to prepare **8** except using **46d** (0.125 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.094 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.815 (t, 1H, J=8.5 Hz), 7.418-7.332 (m, 5H), 6.901 (d, 1H, J=9Hz), 6.801-6.780 (m, 1H), 4.031-3.945 (m, 3H), 3.766-3.695 (m, 2H), 3.599-3.412 (m, 2H), 3.352-3.130 (m, 4H), 3.070-3.010 (m, 1H), 2.958-2.886 (m, 1H). ¹³C NMR (D₂O, 125.7 MHz): δ 154.626 (1C), 144.827 (1C), 144.525 (1C), 133.832 (1C), (129.619+129.592) (2C) 129.553 (2C), 128.296 (1C), 112.868 (1C), 112.574 (1C), (61.189+61.042) (1C), (50.341+50.218) (1C), (48.751+48.717) (1C), (48.260+48.167) (1C), 46.697 (1C), (40.441+40.310) (1C), (36.553+36.526) (1C), (33.803+33.710) (1C). MS (ESI, CH₃OH): [C₁₉H₂₇N₅] *m/z* 326.2 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 326.2339, Found: 326.2336.

6-[(±)-trans-4'-((S)-pyrrolidin-3''-ylamino)pyrrolidin-3'-yl)methyl]pyridin-2-amine tetrahydrochloride (17). The procedure to prepare **17** is the same as that to prepare **8** except using **46e** (0.112 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.081 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.840 (t, 1H, J=8.5Hz), 6.921 (d, 1H, J=9Hz), 6.833 (d, 1H, J=7Hz), 4.289-4.251 (m, 1H), 4.133-4.042 (m, 2H), 3.941-3.864 (m, 1H), 3.776-3.630 (m, 3H), 3.590-3.543 (m, 1H), 3.489-3.436 (m, 1H), 3.378-3.340 (m, 2H), 3.181-3.151 (m, 1H), 2.990-2.940 (m, 1H), 2.694-2.560 (m, 1H), 2.331-2.228 (m, 1H). ¹³C NMR (D₂O, 125.7 MHz): δ 154.781 (1C), 144.831 (1C), 144.541 (1C), (112.837+112.790) (1C), 112.666 (1C), (59.634+59.321) (1C), (55.433+55.278) (1C), (48.573+48.523) (1C), 46.771 (1C), (46.589+46.484) (1C), 44.809 (1C), (40.639+40.503) (1C), (33.687+33.590) (1C), (27.771+27.249) (1C). MS (ESI, CH₃OH): [C₁₄H₂₃N₅] *m/z* 262.2 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 262.2026, Found: 262.2022.

6-[(±)-trans-4'-((R)-pyrrolidin-3''-ylamino)pyrrolidin-3'-yl)methyl]pyridin-2-amine tetrahydrochloride (18). The procedure to prepare **18** is the same as that to prepare **8** except using **46f** (0.112 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.081 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.845-7.815 (m, 1H), 6.918-6.902 (m, 1H), 6.825-6.814 (m, 1H), 4.260-4.249 (m, 1H), 4.082-4.045 (m, 2H), 3.927-3.852 (m, 1H), 3.754-3.632 (m, 3H), 3.564-3.539 (m, 1H), 3.460-3.441 (m, 1H), 3.364-3.330 (m, 2H), 3.149 (m, 1H), 2.975-2.926 (m, 1H), 2.653-2.564 (m, 1H), 2.299-2.258 (m, 1H). ¹³C NMR (D₂O, 125.7 MHz): δ 154.777 (1C), 144.804 (1C), 144.529 (1C), (112.802+112.752) (1C), 112.647 (1C), (59.615+59.298) (1C), (55.409+55.255) (1C), (48.546+48.492) (1C), 46.747 (1C), (46.566+46.461) (1C), 44.782 (1C), (40.623+40.492) (1C), (33.660+33.567) (1C), (27.756+27.230) (1C).

MS (ESI, CH₃OH): [C₁₄H₂₃N₅] *m/z* 262.2 ([M+H]⁺). HRMS (CI⁺, CH₃OH) Calc.: 262.2026, Found: 262.2023.

6-{{(±)-trans-4'-[((S)-1''-benzylpyrrolidin-3''-yl)amino]pyrrolidin-3'-yl}methyl}pyridin-2-amine tetrahydrochloride (19). The procedure to prepare **19** is the same as that to prepare **8** except using **46g** (0.110 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.099 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.805 (t, 1H, J=7.5Hz), 7.518 (m, 5H), 6.912-6.879 (m, 1H), 6.818-6.795 (m, 1H), 4.487 (m, 2H), 4.222 (m, 1H), 4.021-3.841 (m, 3H), 3.713-3.458 (m, 5H), 3.350-3.256 (m, 2H), 3.076-3.069 (m, 1H), 2.971-2.904 (m, 1H), 2.638 (m, 1H), 2.285 (m, 1H). ¹³C NMR (D₂O, 125.7 MHz): δ 154.731 (1C), 144.773 (2C), (130.590+130.571) (2C), 130.501 (1C), 129.627 (2C), (129.472+129.449) (1C), (112.748+112.713) (1C), 112.546 (1C), (59.518+59.147) (1C), (58.810+55.779) (1C), (54.524+54.411+54.202) (2C), 52.454 (1C), (48.570+48.477) (1C), (47.061+46.914) (1C), (40.832+40.786) (1C), (33.698+33.652) (1C), 26.971 (1C). MS (ESI, CH₃OH): [C₂₁H₂₉N₅] *m/z* 352.3 ([M+H]⁺). HRMS (CI⁺, CH₃OH) Calc.: 352.2496, Found: 352.2497.

6-{{(±)-trans-4'-[((R)-1''-benzylpyrrolidin-3''-yl)amino]pyrrolidin-3'-yl}methyl}pyridin-2-amine tetrahydrochloride (20). The procedure to prepare **20** is the same as that to prepare **8** except using **46h**(0.110 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.099 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.809 (t, 1H, J=7.5Hz), 7.521 (m, 5H), 6.9025 (d, 1H, J=8.5Hz), 6.811-6.788 (m, 1H), 4.515-4.450 (m, 2H), 4.154-4.105 (m, 1H), 3.979-3.801 (m, 3H), 3.731-3.505 (m, 5H), 3.324-3.226 (m, 2H), 3.076-2.890 (m, 2H), 2.600 (m, 1H), 2.238 (m, 1H). ¹³C NMR (D₂O, 125.7 MHz): δ 154.742 (1C), 145.009 (1C), 144.769 (1C), 130.571 (2C), 130.486 (1C), 129.619 (2C), 129.546 (1C), 112.697 (1C), 112.469 (1C), (59.534+59.143) (1C), 58.798 (1C), (54.876+54.779) (1C), (54.365+54.152) (1C), 52.500 (1C), (48.535+48.434) (1C), (47.328+47.185) (1C), (41.022+40.964) (1C), 33.725 (1C), 27.694 (1C). MS (ESI, CH₃OH): [C₂₁H₂₉N₅] *m/z* 352.3 ([M+H]⁺). HRMS (CI⁺, CH₃OH) Calc.: 352.2496, Found: 352.2493.

(±)-trans-*tert*-Butyl

3-{{2'-[(*tert*-butoxycarbonyl)(4''-chlorobenzyl)amino]ethyl}amino}-4-{{6'-[(*tert*-butoxycarbonyl)amino]-4'-methylpyridin-2'-yl}methyl}pyrrolidine-1-carboxylate (50b). The procedure to prepare **50b** is the same as that to prepare **42a** except using **49** (0.203 g, 0.5 mmol)² and *tert*-butyl (2-aminoethyl)(4-chlorobenzyl)carbamate (0.156 g, 0.55 mmol)² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9 : 1 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.120 g, 65%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.616-7.600 (m, 1H), 7.292-7.279 (s, 3H), 7.162 (s, 2H), 6.603 (s, 1H), 4.402 (s, 2H), 3.669-3.658 (m, 0.5H), 3.606 (m, 0.5H), 3.553-3.518 (m, 0.5H), 3.464-3.430 (m, 0.5H), 3.379-2.946 (m, 5H), 2.791-2.682 (m, 3H), 2.521-2.501 (m, 1H), 2.409-2.283 (m, 4H), 1.514-1.448 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 157.791 (1C), 155.927 (1C), (154.749+154.658) (1C), 152.533 (1C), 151.531 (1C), 150.032 (1C), 137.179 (1C), 133.038 (1C), (129.110+128.758+128.491) (4C), (119.292+119.226) (1C), (110.386+110.325) (1C), 80.861 (1C), 80.241 (1C), 79.349 (1C), (62.149+61.299) (1C), (51.882+51.330) (1C), 50.407 (1C), (49.915+49.702) (1C), 47.310 (1C), 46.290 (1C), (44.153+43.169) (1C), (39.691+39.594) (1C), 28.598

(3C), 28.556 (3C), 28.374 (3C), 21.398 (1C). MS (ESI, CH₃OH): [C₃₅H₅₂ClN₅O₆] *m/z* 674.3 ([M+H]⁺).

(±)-trans-*tert*-Butyl

3-{{2'-[(*tert*-butoxycarbonyl)(4''-(trifluoromethyl)benzyl)amino]ethyl}amino}-4-{{6'-[(*tert*-butoxycarbonyl)amino]-4'-methylpyridin-2'-yl)methyl}pyrrolidine-1-carboxylate (50d). The procedure to prepare **50d** is the same as that to prepare **42a** except using **49** (0.203 g, 0.5 mmol)² and *tert*-butyl (2-aminoethyl)(4-(trifluoromethyl)benzyl)carbamate (0.175 g, 0.55 mmol)² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9.5 : 0.5 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.110 g, 57%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.615-7.574 (m, 3H), 7.337 (s, 2H), 7.228-7.196 (brs, 1H), 6.601 (s, 1H), 4.497 (s, 2H), 3.700-3.666 (m, 0.5H), 3.621 (m, 0.5H), 3.563-3.527 (m, 0.5H), 3.470-3.434 (m, 0.5H), 3.395-3.214 (m, 2H), 3.133-3.097 (m, 1H), 3.069-3.018 (m, 1H), 2.968-2.955 (m, 1H), 2.800-2.718 (m, 3H), 2.553-2.509 (m, 1H), 2.411-2.247 (m, 4H), 1.513-1.447 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 157.870 (1C), 155.860 (1C), (154.804+154.701) (1C), 152.564 (1C), 151.556 (1C), 150.080 (1C), 142.995 (1C), (130.021+129.760+129.492+129.240) (1C), (127.859+127.264) (2C), (125.643+125.613) (2C), (127.531+125.370+123.202+121.041) (1C), (119.347+119.280) (1C), (110.416+110.349) (1C), 80.940 (1C), 80.430 (1C), 79.410 (1C), (62.246+61.408) (1C), (51.955+51.402) (1C), 50.570 (1C), (49.976+49.769) (1C), (47.681+47.583) (1C), 46.381 (1C), (44.226+43.667) (1C), (39.764+39.679) (1C), 28.653 (3C), 28.544 (3C), 28.410 (3C), 21.428 (1C). ¹⁹F NMR (CDCl₃, 376.5 MHz): δ -62.875 (CF₃). MS (ESI, CH₃OH): [C₃₆H₅₂F₃N₅O₆] *m/z* 708.3 ([M+H]⁺), 730.2([M+Na]⁺).

(±)-trans-*tert*-Butyl

3-{{2'-[(*tert*-butoxycarbonyl)(4''-fluorobenzyl)amino]ethyl}amino}-4-{{6'-[(*tert*-butoxycarbonyl)amino]-4'-methylpyridin-2'-yl)methyl}pyrrolidine-1-carboxylate (50e). The procedure to prepare **50e** is the same as that to prepare **42a** except using **49** (0.203 g, 0.5 mmol)² and *tert*-butyl (2-aminoethyl)(4-fluorobenzyl)carbamate (0.147 g, 0.55 mmol)² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9.5 : 0.5 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.099 g, 55%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.615-7.598 (m, 1H), 7.199 (m, 3H), 7.003 (m, 2H), 6.602 (s, 1H), 4.404 (s, 2H), 3.668-3.657 (m, 0.5H), 3.600 (m, 0.5H), 3.554-3.519 (m, 0.5H), 3.462-3.442 (m, 0.5H), 3.381-3.197 (m, 2H), 3.125-3.091 (m, 1H), 3.047-3.036 (m, 1H), 2.949-2.938 (m, 1H), 2.818-2.677 (m, 3H), 2.523-2.503 (m, 1H), 2.409-2.283 (m, 4H), 1.514-1.449 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ (163.116+161.161) (1C), 157.858 (1C), 155.939 (1C), (154.737+154.646) (1C), 152.527 (1C), 151.519 (1C), 149.995 (1C), 134.337 (1C), (129.420+128.812) (2C), (119.286+119.220) (1C), (115.540+115.370) (2C), (110.361+110.295) (1C), 80.849 (1C), 80.138 (1C), 79.312 (1C), (62.149+61.329) (1C), (51.900+51.354) (1C), 50.285 (1C), (49.921+49.721) (1C), 47.201 (1C), 46.278 (1C), (44.153+43.607) (1C), (39.709+39.624) (1C), 28.617 (3C), 28.556 (3C), 28.368 (3C), 21.385 (1C). ¹⁹F NMR (CDCl₃, 376.5 MHz): δ -115.902 (F). MS (ESI, CH₃OH): [C₃₅H₅₂FN₅O₆] *m/z* 658.3 ([M+H]⁺).

(±)-trans-tert-Butyl

3-{{2'-[(*tert*-butoxycarbonyl)(3''-(trifluoromethyl)benzyl)amino]ethyl}amino}-4-{{6'-[(*tert*-butoxycarbonyl)amino]-4'-methylpyridin-2'-yl}methyl}pyrrolidine-1-carboxylate (50f). The procedure to prepare **50f** is the same as that to prepare **42a** except using **49** (0.203 g, 0.5 mmol)² and *tert*-butyl (2-aminoethyl)(3-(trifluoromethyl)benzyl)carbamate (0.175 g, 0.55 mmol)² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9.5 : 0.5 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.107 g, 55%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.611-7.592 (m, 1H), 7.511-7.430 (m, 4H), 7.217 (brs, 1H), 6.600 (s, 1H), 4.436(s, 2H), 3.692-3.659 (m, 0.5H), 3.607 (m, 0.5H), 3.556-3.520 (m, 0.5H), 3.466-3.430 (m, 0.5H), 3.396-3.217 (m, 2H), 3.130-3.093 (m, 1H), 3.048-3.031 (m, 1H), 2.957-2.906(m, 1H), 2.818-2.719 (m, 3H), 2.575-2.477 (m, 1H), 2.411-2.199 (m, 4H), 1.513-1.447 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 157.919 (1C), 155.848 (1C), (154.792+154.701) (1C), 152.570 (1C), 151.544 (1C), 150.062 (1C), 139.959 (1C), (131.393+131.138+130.883+130.628+130.482) (2C), 129.158 (1C), 124.204 (2C), (127.477+125.309+123.142+120.980) (1C), (119.341+119.268) (1C), (110.404+110.337) (1C), 80.909 (1C), 80.466 (1C), 79.379 (1C), (62.240+61.426) (1C), (51.937+51.773) (1C), 50.800 (1C), (49.957+49.757) (1C), (47.693+47.420) (1C), 46.400 (1C), (44.208+43.661) (1C), (39.757+39.672) (1C), 28.653 (3C), 28.513 (3C), 28.404 (3C), 21.416 (1C). ¹⁹F NMR (CDCl₃, 376.5 MHz): δ -63.069 (CF₃). MS (ESI, CH₃OH): [C₃₆H₅₂F₃N₅O₆] *m/z* 708.3 ([M+H]⁺).

(±)-trans-tert-Butyl

3-{{2'-[(*tert*-butoxycarbonyl)(3''-methylbenzyl)amino]ethyl}amino}-4-{{6'-[(*tert*-butoxycarbonyl)amino]-4'-methylpyridin-2'-yl}methyl}pyrrolidine-1-carboxylate (50g). The procedure to prepare **50g** is the same as that to prepare **42a** except using **49** (0.203 g, 0.5 mmol)² and *tert*-butyl (2-aminoethyl)(3-methylbenzyl)carbamate (0.145 g, 0.55 mmol)² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9.75 : 0.25 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.117 g, 65%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.611-7.593 (m, 1H), 7.203-7.190 (m, 2H), 7.069-7.029 (m, 3H), 6.597 (s, 1H), 4.410 (s, 2H), 3.663-3.656 (m, 0.5H), 3.593 (m, 0.5H), 3.544-3.508 (m, 0.5H), 3.453-3.418 (m, 0.5H), 3.379-3.212 (m, 2H), 3.120-3.084 (m, 1H), 3.028-3.009 (m, 1H), 2.942-2.923 (m, 1H), 2.790-2.678 (m, 3H), 2.529-2.484 (m, 1H), 2.408-2.281 (m, 4H), 1.513-1.450 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 157.925 (1C), 156.109 (1C), (154.749+154.670) (1C), 152.545 (1C), 151.501 (1C), 149.983 (1C), 138.490 (1C), 138.247 (1C), (128.557+128.090) (3C), (124.933+124.320) (1C), (119.305+119.226) (1C), (110.355+110.276) (1C), 80.855 (1C), 80.005 (1C), 79.294 (1C), (62.118+61.293) (1C), (51.937+51.390) (1C), 50.880 (1C), (49.921+49.727) (1C), (47.098+46.946) (1C), 46.260 (1C), (44.159+43.637) (1C), (39.709+39.618) (1C), 28.647 (6C), 28.398 (3C), 21.562 (1C), 21.410 (1C). MS (ESI, CH₃OH): [C₃₆H₅₅N₅O₆] *m/z* 654.5 ([M+H]⁺).

(±)-trans-tert-Butyl

4''-dichlorobenzyl)amino]ethyl}amino}

3-{{2'-[(*tert*-butoxycarbonyl)(3''

-4-{{6'-[(*tert*-butoxycarbonyl)amino]-4'-methylpyridin-2'-yl}methyl}pyrrolidine-1-carboxylate (50h). The procedure to prepare **50h** is the same as that to prepare **42a** except using **49** (0.203 g, 0.5 mmol)² and *tert*-butyl (2-aminoethyl)(3,4-dichlorobenzyl)carbamate (0.175 g, 0.55 mmol)² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 8.5 : 1.5 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.126 g, 65%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.615-7.597 (m, 1H), 7.393-7.317 (s, 3H), 7.072 (s, 1H), 6.605 (s, 1H), 4.387 (s, 2H), 3.701-3.668 (m, 0.5H), 3.628-3.606 (m, 0.5H), 3.544-3.523 (m, 0.5H), 3.473-3.437 (m, 0.5H), 3.380-3.133 (m, 2H), 3.117-3.096 (m, 1H), 3.074-3.022 (m, 1H), 2.973-2.960 (m, 1H), 2.838-2.713 (m, 3H), 2.552-2.508 (m, 1H), 2.408-2.284 (m, 4H), 1.514-1.449 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 157.829 (1C), 155.722 (1C), (154.702+154.599) (1C), 152.498 (1C), 151.527 (1C), 149.961 (1C), 139.141 (1C), (132.608+131.181) (1C), 130.544 (1C), (129.493+129.099) (1C), (127.059+126.403) (1C), (119.257+119.184) (1C), (110.350+110.277) (1C), (80.879+80.806) (1C), 80.411 (1C), 79.288 (1C), (62.167+61.347) (1C), (51.869+51.317) (1C), 50.200 (1C), (49.884+49.690) (1C), (47.534+47.332) (1C), 46.332 (1C), (44.128+43.588) (1C), (39.684+39.599) (1C), 28.585 (3C), 28.470 (3C), 28.336 (3C), 21.360 (1C). MS (ESI, CH₃OH): [C₃₅H₅₁Cl₂N₅O₆] *m/z* 708.5 ([M+H]⁺).

(±)-*trans-tert*-Butyl

3-{{2'-[(*tert*-butoxycarbonyl)(2'',

4''-dichlorobenzyl)amino]ethyl}amino}

-4-{{6'-[(*tert*-butoxycarbonyl)amino]-4'-methylpyridin-2'-yl}methyl}pyrrolidine-1-carboxylate (50i). The procedure to prepare **50i** is the same as that to prepare **42a** except using **49** (0.203 g, 0.5 mmol)² and *tert*-butyl (2-aminoethyl)(2,4-dichlorobenzyl)carbamate (0.175 g, 0.55 mmol)² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9.5 : 0.5 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.126 g, 65%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.615-7.597 (m, 1H), 7.361-7.192 (s, 4H), 6.604 (s, 1H), 4.534-4.510 (s, 2H), 3.705-3.671 (m, 0.5H), 3.632-3.624 (m, 0.5H), 3.565-3.529 (m, 0.5H), 3.475-3.439 (m, 0.5H), 3.394-3.249 (m, 2H), 3.135-3.098 (m, 1H), 3.059-3.024 (m, 1H), 2.978-2.965 (m, 1H), 2.842-2.725 (m, 3H), 2.553-2.511 (m, 1H), 2.438-2.283 (m, 4H), 1.516-1.394 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 157.823 (1C), 155.850 (1C), (154.696+154.599) (1C), 152.504 (1C), 151.503 (1C), 149.936 (1C), (134.745+133.829) (1C), 133.379 (1C), (129.524+129.287+128.728) (2C), 127.259 (1C), (119.245+119.166) (1C), (110.332+110.259) (1C), 80.782 (1C), 80.345 (1C), 79.270 (1C), (62.124+61.317) (1C), (51.869+51.329) (1C), (49.884+49.690) (1C), (48.670+47.990) (1C), 47.601 (1C), 46.308 (1C), (44.146+43.612) (1C), (39.660+39.562) (1C), (28.591+28.342) (9C), 21.360 (1C). MS (ESI, CH₃OH): [C₃₅H₅₁Cl₂N₅O₆] *m/z* 708.5 ([M+H]⁺).

(±)-*trans-tert*-Butyl

3-{{(S)-2'-[(*tert*-butoxycarbonyl)(4''-chlorobenzyl)amino]propyl}amino}-4-{{6'-[(*tert*-butoxycarbonyl)amino]-4'-methylpyridin-2'-yl}methyl}pyrrolidine-1-carboxylate (50j). The procedure to prepare **50j** is the same as that to prepare **42a** except using **49** (0.203 g, 0.5 mmol)² and (S)-*tert*-butyl

(1-aminopropan-2-yl)(4-chlorobenzyl)carbamate (0.164 g, 0.55 mmol)² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 8.5 : 1.5 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.115 g, 61%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.613-7.592 (m, 1H), 7.285-7.215 (m, 5H), 6.595 (s, 1H), 4.298-3.789 (s, 3H), 3.653-3.501 (m, 1.5H), 3.427-3.353 (m, 0.5H), 3.110-2.617 (m, 5H), 2.563-2.411 (m, 3H), 2.311-2.288 (m, 3H), 1.514-1.447 (m, 27H), 1.132-1.015 (m, 3H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 157.987 (1C), 156.311 (1C), (154.830+154.708) (1C), 152.602 (1C), 151.551 (1C), 150.027 (1C), 138.759 (1C), 132.560 (1C), (129.068+128.577+128.261) (4C), (119.342+119.257) (1C), (110.362+110.289) (1C), 80.891 (1C), 80.156 (1C), 79.349 (1C), (62.112+61.500) (1C), 51.784 (3C), 49.708 (1C), (46.939+45.950) (1C), (44.019+43.527) (1C), 39.690 (1C), (28.676+28.421) (9C), 21.445 (1C), 17.007 (1C). MS (ESI, CH₃OH): [C₃₆H₅₄ClN₅O₆] *m/z* 688.5 ([M+H]⁺).

(±)-*trans-tert*-Butyl

3-{{6'-[(*tert*-butoxycarbonyl)amino]-4'-methylpyridin-2'-yl)methyl}-4-{{2'-[(4''-chlorobenzyl)amino]ethyl}(methyl)amino}pyrrolidine-1-carboxylate (50k). The procedure to prepare **50k** is the same as that to prepare **42a** except using **49** (0.203 g, 0.5 mmol)² and *tert*-butyl 4-chlorobenzyl[2'-(methylamino)ethyl]carbamate (0.164 g, 0.55 mmol)² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9.5 : 0.5 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.102 g, 63%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.604-7.583 (m, 1H), 7.343-7.159 (s, 5H), 6.596 (s, 1H), 4.574-4.417 (m, 2H), 3.549-3.515 (m, 0.5H), 3.471-3.123 (m, 4.5H), 2.998-2.943 (m, 3H), 2.626-2.425 (m, 4H), 2.229-2.273 (m, 6H), 1.520-1.414 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ 158.145 (1C), (155.977+155.558) (1C), 154.806 (1C), 152.583 (1C), 151.491 (1C), 149.857 (1C), (137.405+137.186) (1C), 133.009 (1C), (129.208+128.753+128.516) (4C), 119.105 (1C), (110.259+110.144) (1C), 80.794 (1C), 80.011 (1C), 79.404 (1C), (68.554+68.256+67.953+67.358) (1C), 52.325 (1C), (50.910+50.364) (1C), (50.090+49.860) (1C), 45.112 (1C), (44.183+43.958+43.679) (1C), (40.595+40.121+39.811+39.520) (2C), (39.119+38.998+38.281+38.117) (1C), (28.628+28.397) (9C), 21.390 (1C). MS (ESI, CH₃OH): [C₃₆H₅₄ClN₅O₆] *m/z* 688.4 ([M+H]⁺).

(±)-*trans-tert*-Butyl

3-{{2'-[(*tert*-butoxycarbonyl)(4''-fluorophenethyl)amino]ethyl}amino}-4-{{6'-[(*tert*-butoxycarbonyl)amino]-4'-methylpyridin-2'-yl)methyl}pyrrolidine-1-carboxylate (50m). The procedure to prepare **50m** is the same as that to prepare **42a** except using **49** (0.203 g, 0.5 mmol)² and *tert*-butyl (2-aminoethyl)(4-fluorophenethyl)carbamate (0.155 g, 0.55 mmol)² instead of **40** (0.434 g, 0.001 mol) and 3-phenyl-1-propylamine (0.203 g, 0.0015 mol). The desired product was purified by column chromatography (silica gel, hexanes : EtOAc : Et₃N = 9.25 : 0.75 : 0.5, the isomer with lower *R_f* value, *R_f* = 0.1) to afford a pale-yellow oil (0.118 g, 64%, diastereomer ratio: *cis* : *trans* = 45 : 55). ¹H NMR (CDCl₃, 500 MHz): δ 7.616-7.600 (m, 1H), 7.426 (brs, 1H), 7.119 (m, 2H), 6.982-6.950 (m, 2H), 6.603 (s, 1H), 3.706-3.672 (m, 0.5H), 3.637-3.615 (m, 0.5H), 3.559-3.523 (m, 0.5H), 3.478-3.442 (m, 0.5H), 3.365 (m, 2H), 3.217-2.983 (m, 5H),

2.853-2.776 (m, 3H), 2.689 (m, 2H), 2.553-2.510 (m, 1H), 2.406-2.384 (m, 0.5H), 2.294-2.274 (m, 3.5H), 1.511-1.445 (m, 27H). ¹³C NMR (CDCl₃, 125.7 MHz): δ (162.504+160.561) (1C), 157.775 (1C), 155.577 (1C), (154.617+154.526) (1C), 152.450 (1C), 151.472 (1C), 149.857 (1C), (134.849+134.824) (1C), (130.295+130.234) (2C), (119.166+119.087) (1C), (115.341+115.171) (2C), (110.283+110.204) (1C), 80.679 (1C), 79.586 (1C), 79.167 (1C), (62.124+61.292) (1C), (51.815+51.250) (1C), (49.878+49.828) (1C), (49.714+49.635) (1C), (48.287+47.559+47.261) (1C), 46.344 (1C), (44.037+43.527) (1C), 39.538 (1C), (34.408+33.734) (1C), 28.500 (3C), 28.415 (3C), 28.257 (3C), 21.275 (1C). ¹⁹F NMR (CDCl₃, 376.5 MHz): δ -117.349. MS (ESI, CH₃OH): [C₃₆H₅₄FN₅O₆] *m/z* 672.4 ([M+H]⁺).

***N*¹-{(±)-trans-4-[(6'-amino-4'-methylpyridin-2'-yl)methyl]pyrrolidin-3-yl}-*N*²-(4-chlorobenzyl)ethane-1,2-diamine tetrahydrochloride (22).** The procedure to prepare **22** is the same as that to prepare **8** except using **50b** (0.135 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.103 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.456-7.430 (m, 4H), 6.692 (s, 1H), 6.673 (s, 1H), 4.306 (s, 2H), 4.102-3.990 (m, 2H), 3.749-3.713 (m, 1H), 3.688-3.648 (m, 1H), 3.548-3.542 (m, 4H), 3.341-3.243 (m, 2H), 3.118-3.088 (m, 1H), 2.898-2.848 (m, 1H), 2.307 (s, 3H). ¹³C NMR (D₂O, 125.7 MHz): δ 158.334 (1C), 154.229 (1C), 143.495 (1C), 135.542 (1C), 131.620 (2C), 129.501 (2C), 128.754 (1C), 114.996 (1C), 111.311 (1C), 60.749 (1C), 51.132 (1C), 48.569 (1C), 46.384 (1C), 42.917 (1C), 42.735 (1C), 40.452 (1C), 33.397 (1C), 21.333 (1C). MS (ESI, CH₃OH): [C₂₀H₂₈ClN₅] *m/z* 374.4 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 374.2106, Found: 374.2102.

***N*¹-{(±)-trans-4-[(6'-amino-4'-methylpyridin-2'-yl)methyl]pyrrolidin-3-yl}-*N*²-[4'-(trifluoromethyl)benzyl]ethane-1,2-diamine tetrahydrochloride (24).** The procedure to prepare **24** is the same as that to prepare **8** except using **50d** (0.141 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.110 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.792 (s, 2H), 7.679 (s, 2H), 6.707 (s, 2H), 4.435 (s, 2H), 4.081-4.022 (m, 2H), 3.770-3.684 (m, 2H), 3.598 (m, 4H), 3.356-3.277 (m, 2H), 3.134 (m, 1H), 2.930-2.883 (m, 1H), 2.333 (s, 3H). ¹³C NMR (D₂O, 125.7 MHz): δ 158.392 (1C), 154.251 (1C), 143.589 (1C), (131.625+131.379+131.118+130.861) (1C), 130.576 (2C), 126.387 (2C), (127.258+125.095+122.932+120.800) (1C), 115.039 (1C), 111.319 (1C), 60.815 (1C), 51.221 (1C), 48.604 (1C), 46.526 (1C), 43.123 (1C), 42.955 (1C), 40.559 (1C), 33.448 (1C), 21.370 (1C). ¹⁹F NMR (D₂O, 376.5 MHz): δ -62.988 (CF₃). MS (ESI, CH₃OH): [C₂₁H₂₈F₃N₅] *m/z* 408.3 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 408.2370, Found: 408.2363.

***N*¹-{(±)-trans-4-[(6'-amino-4'-methylpyridin-2'-yl)methyl]pyrrolidin-3-yl}-*N*²-(4'-fluorobenzyl)ethane-1,2-diamine tetrahydrochloride (25).** The procedure to prepare **25** is the same as that to prepare **8** except using **50e** (0.131 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.100 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.509 (m, 2H), 7.207-7.173 (m, 2H), 6.705 (s, 1H), 6.686 (s, 1H), 4.316 (s, 2H), 4.083-4.004 (m, 2H), 3.765-3.731 (m, 1H), 3.702-3.662 (m, 1H), 3.589-3.550 (m, 4H), 3.354-3.262 (m, 2H), 3.129 (m, 1H), 2.913-2.863 (m, 1H), 2.317 (s, 3H). ¹³C NMR (D₂O, 125.7 MHz): δ (164.432+162.465) (1C), 158.380 (1C), 154.251 (1C), 143.517 (1C), (132.366+132.298) (2C), 126.198 (1C), (116.447+116.275) (2C), 115.035 (1C), 111.335 (1C), 60.775 (1C), 51.165 (1C),

48.608 (1C), 46.418 (1C), 42.955 (1C), 42.650 (1C), 40.471 (1C), 33.420 (1C), 21.362 (1C). ¹⁹F NMR (D₂O, 376.5 MHz): δ -112.169 (F). MS (ESI, CH₃OH): [C₂₀H₂₈FN₅] *m/z* 358.3 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 358.2402, Found: 358.2400.

***N*¹-{(±)-trans-4-[(6'-amino-4'-methylpyridin-2'-yl)methyl]pyrrolidin-3-yl}-*N*²-[3'-(trifluoromethyl)benzyl]ethane-1,2-diamine tetrahydrochloride (26).** The procedure to prepare **26** is the same as that to prepare **8** except using **50f** (0.141 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.110 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.855 (m, 1H), 7.821-7.806 (m, 1H), 7.771-7.756 (m, 1H), 7.682-7.652 (m, 1H), 6.724 (s, 1H), 6.704 (s, 1H), 4.436 (s, 2H), 4.071-4.013 (m, 2H), 3.761-3.678 (m, 2H), 3.588 (m, 4H), 3.367-3.273 (m, 2H), 3.127-3.119 (m, 1H), 2.927-2.877 (m, 1H), 2.337 (s, 3H). ¹³C NMR (D₂O, 125.7 MHz): δ 158.380 (1C), 154.255 (1C), 143.605 (1C), 133.766 (1C), 131.073 (1C), (131.270+131.013+130.752+130.490) (1C), 130.275 (1C), 126.904 (2C), (127.170+125.010+122.843+120.680) (1C), 115.007 (1C), 111.307 (1C), 60.799 (1C), 51.253 (1C), 48.584 (1C), 46.530 (1C), 43.043 (1C), 42.938 (1C), 40.559 (1C), 33.436 (1C), 21.342 (1C). ¹⁹F NMR (D₂O, 376.5 MHz): δ -62.879 (CF₃). MS (ESI, CH₃OH): [C₂₁H₂₈F₃N₅] *m/z* 408.3 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 408.2370, Found: 408.2361.

***N*¹-{(±)-trans-4-[(6'-amino-4'-methylpyridin-2'-yl)methyl]pyrrolidin-3-yl}-*N*²-(3'-methylbenzyl)ethane-1,2-diamine tetrahydrochloride (27).** The procedure to prepare **27** is the same as that to prepare **8** except using **50g** (0.131 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.099 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.366-7.297 (m, 4H), 6.705-6.692 (m, 2H), 4.286 (s, 2H), 4.077-4.002 (m, 2H), 3.761-3.666 (m, 2H), 3.550-3.544 (m, 4H), 3.371-3.320 (m, 2H), 3.126-3.117 (m, 1H), 2.913-2.863 (m, 1H), 2.335-2.324 (s, 6H). ¹³C NMR (D₂O, 125.7 MHz): δ 158.372 (1C), 154.235 (1C), 143.553 (1C), 139.793 (1C), 130.721 (1C), 130.592 (1C), 130.115 (1C), 129.445 (1C), 126.961 (1C), 115.039 (1C), 111.331 (1C), 60.771 (1C), 51.859 (1C), 48.617 (1C), 46.494 (1C), 42.971 (1C), 42.730 (1C), 40.519 (1C), 33.444 (1C), 21.386 (1C), 20.576 (1C). MS (ESI, CH₃OH): [C₂₁H₃₁N₅] *m/z* 354.3 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 354.2652, Found: 354.2652.

***N*¹-{(±)-trans-4-[(6'-amino-4'-methylpyridin-2'-yl)methyl]pyrrolidin-3-yl}-*N*²-(3,4-dichlorobenzyl)ethane-1,2-diamine tetrahydrochloride (28).** The procedure to prepare **28** is the same as that to prepare **8** except using **50h** (0.141 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.110 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.630 (s, 1H), 7.551-7.535 (m, 1H), 7.387-7.371 (m, 1H), 6.658 (s, 2H), 4.300 (s, 2H), 4.077-3.996 (m, 2H), 3.753-3.726 (m, 1H), 3.689-3.652 (m, 1H), 3.593-3.557 (m, 4H), 3.340-3.247 (m, 2H), 3.109-3.102 (m, 1H), 2.895-2.845 (m, 1H), 2.284 (s, 3H). ¹³C NMR (D₂O, 125.7 MHz): δ 158.328 (1C), 154.188 (1C), 143.490 (1C), 133.733 (1C), 132.634 (1C), 131.960 (1C), 131.407 (1C), 130.436 (1C), 129.805 (1C), 115.051 (1C), 111.311 (1C), 60.796 (1C), 50.590 (1C), 48.605 (1C), 46.449 (1C), 42.946 (2C), 40.523 (1C), 33.444 (1C), (21.429+21.392) (1C). MS (ESI, CH₃OH): [C₂₀H₂₇Cl₂N₅] *m/z* 408.5 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 408.1716, Found: 408.1704; [C₂₀H₂₈Cl³⁷ClN₅] Calc.: 410.1687, Found: 410.1679.

***N*¹-{(±)-trans-4-[(6'-amino-4'-methylpyridin-2'-yl)methyl]pyrrolidin-3-yl}-*N*²-(2,4-dichlorobenzyl)ethane-1,2-diamine tetrahydrochloride (29).** The procedure to


prepare **29** is the same as that to prepare **8** except using **50i** (0.141 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.110 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.546 (s, 1H), 7.4805 (d, 1H, J=8.5Hz), 7.366 (d, 1H, J=8Hz), 6.641 (s, 1H), 6.627 (s, 1H), 4.411 (s, 2H), 4.042-3.951 (m, 2H), 3.714-3.677 (m, 1H), 3.643-3.603 (m, 1H), 3.585-3.506 (m, 4H), 3.299-3.204 (m, 2H), 3.080-3.060 (m, 1H), 2.857-2.806 (m, 1H), 2.256 (s, 3H). ¹³C NMR (D₂O, 125.7 MHz): δ 158.328 (1C), 154.230 (1C), 143.465 (1C), 136.611 (1C), 135.311 (1C), 133.302 (1C), (129.987+129.956) (1C), 128.281 (1C), 126.757 (1C), 115.014 (1C), 111.317 (1C), 60.760 (1C), 48.623 (1C), 48.586 (1C), 46.370 (1C), 43.067 (1C), 42.861 (1C), 40.469 (1C), 33.389 (1C), (21.368+21.325) (1C). MS (ESI, CH₃OH): [C₂₀H₂₇Cl₂N₅] *m/z* 408.4 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 408.1716, Found: 408.1703; [C₂₀H₂₈Cl³⁷CIN₅] Calc.: 410.1687, Found: 410.1681.


(S)-N¹-{(±)-trans-4-[(6'-amino-4'-methylpyridin-2'-yl)methyl]pyrrolidin-3-yl}-N²-(3,4-dichlorobenzyl)propane-1,2-diamine tetrahydrochloride (30). The procedure to prepare **30** is the same as that to prepare **8** except using **50j** (0.137 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.113 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.425 (m, 4H), 6.651 (s, 2H), 4.350-4.224 (m, 2H), 3.995-3.945 (m, 2H), 3.883-3.781 (m, 1H), 3.661-3.635 (m, 2H), 3.555-3.245 (m, 3H), 3.161-3.132 (m, 1H), 3.051 (m, 1H), 2.871-2.789 (m, 1H), 2.276 (s, 3H), 1.520-1.509 (m, 3H). ¹³C NMR (D₂O, 125.7 MHz): δ 158.341 (1C), 154.206 (1C), 143.757 (1C), 135.427 (1C), (131.590+131.541) (2C), 129.489 (2C), 129.009 (1C), (115.075+114.984) (1C), 111.256 (1C), (61.385+61.318) (1C), (51.640+51.452) (1C), (48.696+48.647+48.544) (2C), (47.129+46.813+46.680) (1C), (40.566+40.536) (1C), (33.796+33.559) (1C), (21.380+21.350) (1C), (14.398+14.337) (1C). MS (ESI, CH₃OH): [C₂₁H₃₀ClN₅] *m/z* 388.4 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 388.2263, Found: 388.2258.


N¹-{(±)-trans-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N²-(4-chlorobenzyl)-N¹-methylethane-1,2-diamine tetrahydrochloride (31). The procedure to prepare **31** is the same as that to prepare **8** except using **50k** (0.137 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.113 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.429-7.403 (m, 4H), 6.658 (s, 1H), 6.638 (s, 1H), 4.306 (s, 2H), 4.247-4.236 (m, 1H), 4.017-3.973 (m, 1H), 3.819-3.781 (m, 1H), 3.630-3.563 (m, 5H), 3.282-3.203 (m, 3H), 3.002 (s, 3H), 2.904-2.855 (m, 1H), 2.266 (s, 3H). ¹³C NMR (D₂O, 125.7 MHz): δ 158.304 (1C), 154.151 (1C), 143.417 (1C), 135.524 (1C), 131.747 (2C), 129.501 (2C), 128.760 (1C), 115.136 (1C), 111.335 (1C), 68.124 (1C), 51.185 (1C), 50.887 (1C), 48.793 (1C), 44.561 (1C), 41.683 (1C), 38.004 (1C), 37.512 (1C), 34.118 (1C), (21.465+21.429) (1C). MS (ESI, CH₃OH): [C₂₁H₃₀ClN₅] *m/z* 388.4 ([M+H]⁺). HRMS (CI+, CH₃OH) Calc.: 388.2263, Found: 388.2261.


N¹-{(±)-trans-4-[(6'-amino-4'-methylpyridin-2'-yl)methyl]pyrrolidin-3-yl}-N²-(4-fluorophenethyl)ethane-1,2-diamine tetrahydrochloride (33). The procedure to prepare **33** is the same as that to prepare **8** except using **50m** (0.134 g, 0.2 mmol) instead of **42a**, affording a hygroscopic white solid (0.103 g, quantitative yield). ¹H NMR (D₂O, 500 MHz): δ 7.285-7.258 (m, 2H), 7.073-7.037 (m, 2H), 6.660-6.630 (s, 2H), 4.078-3.996 (m, 2H), 3.762-3.736 (m, 1H), 3.687-3.648 (m, 1H), 3.554-3.511 (m, 4H), 3.384-3.239 (m, 4H), 3.107 (m, 1H), 3.011-2.982 (m, 2H), 2.895-2.845 (m, 1H), 2.284-2.264 (s, 3H). ¹³C NMR (D₂O, 125.7 MHz): δ


(162.894+162.858+160.963+160.921) (1C), (158.236+158.268) (1C),
(154.139+154.084) (1C), (143.423+143.387) (1C), (131.826+131.808) (1C),
(130.819+130.725) (2C), (115.889+115.719) (2C), 115.051 (1C), 111.293 (1C), 60.748
(1C), 49.552 (1C), 48.592 (1C), 46.395 (1C), 43.371 (1C), 42.952 (1C), 40.475 (1C),
33.402 (1C), 31.125 (1C), (21.410+21.398) (1C). ¹⁹F NMR (D₂O, 376.5 MHz): δ
-116.242. MS (ESI, CH₃OH): [C₂₁H₃₀FN₅] *m/z*. 372.4 ([M+H]⁺). HRMS (CI+,
CH₃OH) Calc.: 372.2558, Found: 372.2557.

















































































































































































References:

- ¹ Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated Docking using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. *J. Comp. Chem.* **1998**, *19*(14), 1639–1662.
- ² Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; Alagona, G.; Profeta, S.; Weiner, P. A New Force Field for Molecular Mechanical Simulation of Nucleic Acid and Proteins. *J. Am. Chem. Soc.* **1984**, *106*(3), 765–784.
- ³ Gasteiger, J.; Marsili, M. Iterative Paratotal Equalization of Orbital Electronegativity – a Rapid Access to Atomic Charges. *Tetrahedron* **1980**, *36*(22), 3219–3228.
- ⁴ Ji, H.; Li, H.; Flinspach, M.; Poulos, T. L.; Silverman, R. B. Computer Modeling of Selective Regions in the Active Site of Nitric Oxide Synthases: Implication for the Design of Isoform-Selective Inhibitors. *J. Med. Chem.* **2003**, *46*(26), 5700–5711.
- ⁵ Ji, H.; Stanton, B. Z.; Igarashi, J.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Minimal Pharmacophoric Elements and Fragment Hopping, An Approach Directed at Molecular Diversity and Isozyme Selectivity. Design of Selective Neuronal Nitric Oxide Synthase Inhibitors. *J. Am. Chem. Soc.* **2008**, *130*(12), 3900–3914.
- ⁶ Ji, H.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Discovery of Highly Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase by Fragment Hopping. *J. Med. Chem.* **2009**, *52*(3), 779–797.